Skip to content
Current Assets

Net Cash Collateral Received - Derivative Instruments

Medtronic Net Cash Collateral Received - Derivative Instruments decreased by 53.9% to $125M in Q1 2025 compared to the prior quarter. Over 2 years (FY 2021 to FY 2024), Net Cash Collateral Received - Derivative Instruments shows an upward trend with a 375.2% CAGR.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ1 2015
Last reportedQ1 2025Feb 24, 2026
Metric ID: net_cash_collateral_received_derivatives

Historical Data

13 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q4 '24Q1 '25
Value$0$0$12M$0$0$1M$6M$0$29M$92M$52M$271M$125M
QoQ Change-100.0%+500.0%-100.0%+217.2%-43.5%+421.2%-53.9%
YoY Change-100.0%>999%+834.5%
Range$0$271M
Avg YoY Growth+722.6%
Median YoY Growth+834.5%

Frequently Asked Questions

What is Medtronic's net cash collateral received - derivative instruments?
Medtronic (MDT) reported net cash collateral received - derivative instruments of $125M in Q1 2025.
What is the long-term trend for Medtronic's net cash collateral received - derivative instruments?
Over 2 years (2021 to 2024), Medtronic's net cash collateral received - derivative instruments has grown at a 375.2% compound annual growth rate (CAGR), from $12M to $271M.